2023
DOI: 10.1016/j.tig.2022.12.001
|View full text |Cite
|
Sign up to set email alerts
|

Clinical progress in genome-editing technology and in vivo delivery techniques

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 56 publications
0
5
0
Order By: Relevance
“…Targeted delivery allows for reduction of potential side effects and increased payload delivery. 2 , 3 Nanoparticles (NPs) can achieve organ/cell specificity (through both passive and active targeting methods), payload release control, and solubility improvement. 3 Lipid nanoparticles (LNPs) in particular have emerged as a promising delivery vehicle for mRNA due to their ability to protect the mRNA and achieve targeting specificity.…”
Section: Main Textmentioning
confidence: 99%
“…Targeted delivery allows for reduction of potential side effects and increased payload delivery. 2 , 3 Nanoparticles (NPs) can achieve organ/cell specificity (through both passive and active targeting methods), payload release control, and solubility improvement. 3 Lipid nanoparticles (LNPs) in particular have emerged as a promising delivery vehicle for mRNA due to their ability to protect the mRNA and achieve targeting specificity.…”
Section: Main Textmentioning
confidence: 99%
“…Messenger RNA (mRNA) technology represents a versatile and potent strategy for the development of next-generation vaccines and therapeutics. [2][3][4] The food and drug administration (FDA)'s approval of the mRNA vaccines from Pfizer-BioNTech and Moderna for COVID-19 has underscored the significant potential of mRNA technology, whose rising signals a pivotal shift in the domain of gene editing, preventive and therapeutic vaccines, anti-tumor immunotherapy, and protein replacement therapies. [5][6][7] To achieve effective mRNA therapies, it is imperative that the mRNAs reach the cytoplasm and be translated into therapeutic proteins.…”
Section: Introductionmentioning
confidence: 99%
“…Gene editing technologies aim to specifically change the target sequences of genetic material. It includes zinc-finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeat-associated protein (CRISPR/Cas) [ 7 9 ]. The progress of gene editing technology not only provides technical support for genetic research but also provides new therapeutic options for medicine.…”
Section: Introductionmentioning
confidence: 99%